1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
Competitor Analysis: Dengue Virus Vaccines, Antibodies & Antivirals

Competitor Analysis: Dengue Virus Vaccines, Antibodies & Antivirals

  • February 2016
  • 42 pages
  • ID: 3686480

Summary

Table of Contents

Search Inside

Competitor Analysis: Dengue Virus Vaccines, Antibodies & Antivirals

This Competitive Intelligence Report provides a competitor evaluation in the field of approved and investigational vaccines and therapeutics against one or more serotypes of Dengue Virus for prophylaxis or treatment of Dengue fever as of February 2016. The report covers live attenuated or whole virus vaccines, recombinant subunit and DNA-based vaccines for prophylaxis of Dengue fever as well as therapeutic antibodies and other antivirals directed against Dengue Virus. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

Dengue virus (DENV) is a mosquito-borne flavivirus that infects at least 390 million people per year. It is estimated that nearly half the world's population is at risk for dengue infection. The primary mosquito vector for dengue, Aedes aegypti, continues to spread widely and into new habitats due to increased urbanization and climate change.

Dengue vaccines could have beneficial individual-level effects by reducing the probability of infection given exposure to an infected mosquito. In addition, with increasing vaccine coverage in a population, vaccines could reduce the overall transmission in the entire community, even to unvaccinated people, and thus have indirect or herd effects. The first Dengue vaccine only recently has been approved in three countries and several more vaccine candidates are in the pipeline.

Therapeutic antibodies and other antiviral agents might help in the post-exposure prophylaxis and treatment of Dengue virus-infected indivivuals. Several candidates are in the development pipeline. Preclinical studies of a candidate antibody have demonstrated a rapid reduction in viral titers after a single systemic administration, which supports its continued development as a single administration for the treatment of dengue virus infection.

The report includes a compilation of currently active projects in research and development of vaccines targeting Dengue virus for prophylaxis of Dengue fever and of therapeutics for treatment of Dengue fever. In addition, the report lists company-specific R&D pipelines of Dengue Virus Vaccines, Antibodies and Antivirals. Competitor projects are listed in a tabular format providing information on:

  • Drug Codes,
  • Target / Mechanism of Action,
  • Class of Compound,
  • Company,
  • Product Category,
  • Indication,
  • R&D Stage and
  • additional comments with a hyperlink leading to the source of information.

About Competitor Analysis Series:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Cholera Vaccines Market Size, Share & Trends Analysis Report By Product, By Region And Segment Forecasts, 2018 - 2025

Cholera Vaccines Market Size, Share & Trends Analysis Report By Product, By Region And Segment Forecasts, 2018 - 2025

  • $ 5950
  • Industry report
  • August 2018
  • by Grand View Research

Cholera Vaccines Market Size, Share & Trends Analysis Report By Product (Dukoral, Shanchol, Vaxchora), By Region (North America, APAC, Europe, MEA, Latin America), And Segment Forecasts, 2018 - 2025The ...

Global Veterinary Vaccines Industry

Global Veterinary Vaccines Industry

  • $ 5600
  • Industry report
  • September 2018
  • by Global Industry Analysts

This report analyzes the worldwide markets for Veterinary Vaccines in US$ by the following Product Segments: Companion Animal Vaccines (Canine Vaccines, & Feline Vaccines), and Livestock Vaccines (Porcine ...

Vaccines Market by Technology, Disease, Route, Patient, Type - Global Forecast to 2023

Vaccines Market: Global Forecast until 2023

  • $ 5649
  • Industry report
  • August 2018
  • by MarketsandMarkets

Global vaccines market projected to grow at a CAGR of 6.7%The vaccines market is expected to reach USD 50.42 billion by 2023 from USD 36.45 billion in 2018, at a CAGR of 6.7%. Rising prevalence of diseases, ...

Cancer Vaccines: Analytical Tool $ 3950 September 2018


ref:plp2016

Reportlinker.com © Copyright 2018. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on